Company Name, Ticker, Customers, else..

Impel Pharmaceuticals Inc (NASDAQ: IMPL)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Impel Pharmaceuticals Inc 's

Name: Impel Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IMPL Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Impel Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2023 by 55.52 % year on year.
The sales growth was above Impel Pharmaceuticals Inc 's competitors' average revenue growth of 31.1 %, achieved in the same quarter.

• List of IMPL Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Impel Pharmaceuticals Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< IMPL Stock Performance Comparisons

<< See the full list of IMPL competitors

Overall company Market Share Q3 2023

Due to outstanding performance in Overall company, revenue grew by 55.52 % Impel Pharmaceuticals Inc improved its market share, to approximately 0.25 %. << More on IMPL Market Share.

*Market share is calculated based on total revenue.

IMPL's Stock Performance relative to its Competitors

Publicly Traded Peers of Impel Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc
Share Performance

+20.24%

This Quarter

Catalyst Pharmaceuticals Inc

Profile

Catalyst Pharmaceuticals Inc operates under a business model where it develops and commercializes novel drugs to address unmet medical needs primarily in the field of rare diseases. The company focuses on conducting clinical research, obtaining necessary regulatory approvals, and marketing its products to healthcare professionals and patients. Catalyst Pharmaceuticals Inc aims to generate revenue through the sale of its approved drugs and by seeking partnerships or collaborations for the development and commercialization of new products.

More about Catalyst Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3,996.188 mill.	$ 596.958 mill.	$ 221.323 mill.

Gain Therapeutics inc
Share Performance

-6.77%

One Year

Gain Therapeutics inc

Profile

Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.

More about Gain Therapeutics inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 75.592 mill.	$ - mill.	$ -21.240 mill.

Gossamer Bio Inc
Share Performance

-93.31%

One Year

Gossamer Bio Inc

Profile

Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.

More about Gossamer Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 56.780 mill.	$ 53.286 mill.	$ -123.445 mill.

Opus Genetics Inc
Share Performance

+8.01%

This Quarter

Opus Genetics Inc

Profile

Opus Genetics develops gene therapies for inherited retinal diseases and other ophthalmic disorders.

More about Opus Genetics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 386.667 mill.	$ 11.983 mill.	$ -106.932 mill.

Karuna Therapeutics Inc
Share Performance

+74.20%

One Year

Karuna Therapeutics Inc

Profile

Karuna Therapeutics Inc's business model revolves around developing innovative therapies for neuropsychiatric disorders by leveraging the potential of its proprietary platform, targeting the muscarinic cholinergic receptors in the brain.

More about Karuna Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 12,190.187 mill.	$ - mill.	$ -433.680 mill.

22 more competitors available

Sources: Impel Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Wednesday, September 2, 2026 9:32 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Impel Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.